Although the first-to-file provisions of the America Invents Act (“AIA”) do not take effect until March 16, 2013, public comments on the USPTO’s proposed implementing regulations are due by Friday, October 5, 2012. The USPTO has demonstrated that it takes public comments seriously, and modified some of the proposed rules for the provisions that took effect on September 16, 2012 in view of public comments. Applicants, practitioners and other stakeholders should not miss this opportunity to shape how the USPTO implements these significant changes to U.S. patent law.
Controversial Proposed Rules
The following proposed rules have garnered attention from commentators:
Formal Requirements
- the requirement that certified copies of foreign priority applications be filed within certain (early) time periods
- the requirement for nonprovisional applications that straddle the first-to-file effective date, for applicants to identify applications that include claims with an effective filing date on or after March 16, 2013, or that include additional disclosure as compare to the earlier application
- the ability of applicants to identify grace period inventor disclosures in the specification
The Meaning of “Sale” in § 102(a)(1)
- the extent to which a “sale” must be “public” in order to qualify as prior art under § 102(a)(1)
Requirements for Invoking the Exceptions To § 102
- the requirement (for all exceptions) to show that the inventor(s) invented the subject matter at issue
- the requirement (for the exception for inventor-originated disclosures) to show an enabling communication from the inventor to another
- the requirement (for the exception for shielding disclosures) of near identity between the shielding disclosure and the disclosure being disqualified
- the ability of the USPTO to require an applicant to file a petition to institute a derivation proceeding if the applicant attempts to disqualify the prior art effect of a pending U.S. application that claims the same subject matter
Submitting Comments
Members of the public can submit written comments by email:
by postal mail:
Mail Stop Comments–Patents
Commissioner for Patents
P.O. Box 1450
Alexandria, VA, 22313-1450
Attention: Susy Tsang-Foster, Legal Advisor, Office of Patent Legal Administration
or via the Federal eRulemaking Portal (see http://www.regulations.gov).
Disclaimer
This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.
Related Insights
23 December 2024
Labor & Employment Law Perspectives
Regulating Artificial Intelligence in Employment Decision-Making: What’s on the Horizon for 2025
Share on TwitterShare by EmailShareBack to topEmployment law in 2024 could aptly be summarized as the “Year of Artificial Intelligence Legislation.
23 December 2024
Health Care Law Today
Medicare Telehealth Flexibilities Get a Three-Month Lifeline
Share on TwitterShare by EmailShareBack to topAfter much uncertainty, Congress has extended many Medicare telehealth flexibilities through March 31, 2025, in its end-of-year appropriations bill.
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.